ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Deferred Liabilities
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Deferred Liabilities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2025-02-19
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in deferred liabilities for fiscal 2024 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in deferred liabilities for fiscal 2023 was -$1.62M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in deferred liabilities for fiscal 2022 was -$1.64M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in deferred liabilities for fiscal 2021 was $0.00.
| Period end | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-19 |
| 2023-12-31 | -$1.62M 10-K · filed 2025-02-19 |
| 2022-12-31 | -$1.64M 10-K · filed 2025-02-19 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-21 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-17 |
| 2019-12-31 | $2.14M 10-K · filed 2022-02-15 |
| 2017-12-31 | -$16.25M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |